Impact of Vitamin B12 on outcome of Early Stage Luminal A and B Breast Cancer, single center experience


  • Saeed M. Shaaban Clinical oncology department, faculty of medicine, Beni-Suef University, Egypt
  • Zeinab Gaber Clinical oncology department, faculty of medicine, Beni-Suef University, Egypt
  • Samah Semary Clinical oncology department, faculty of medicine, Beni-Suef University, Egypt
  • Ahmad M.Dewidar Clinical oncology department, faculty of medicine, Beni-Suef University, Egypt.



Breast Neoplasms, Medical Oncology, Retrospective Studies, Egypt


Background: Despite the fact that many studies have shown that vitamin B12 has no benefit in chemotherapy-induced peripheral neuropathy, many doctors describe vitamin B12 for chemotherapy or hormonal treatment. Some studies have shown that it is effective in cancer treatment-related fatigue, especially with B12 deficiency anaemia. Vitamin B12 has anti-oxidant properties through a variety of mechanisms. Many clinical recommendations are against using antioxidants during cancer treatment; there is concern that using dietary supplements, particularly antioxidants, during treatment may reduce treatment efficacy.

Methods: This is a retrospective study as part of Zeinab Gaber's thesis that reviewed the electronic records of 129 female breast cancer patients with stage I and II luminal (A&B) who were treated at the clinical oncology department, faculty of medicine, Beni-Suef University, Egypt, from the beginning of January 2015 to the end of December 2019.

Results: There was no disease-free survival (DFS) difference in luminal A breast cancer that received or did not receive vitamin B12, with median DFS 80 months versus 81 months for received and not received Vitamin B12, respectively (SE 2.55-3.54, 95% CI, 0.74 to 0.88; P 0.843), and there was no DFS difference in luminal B breast cancer that received or did not receive Vitamin B12, with median DFS 76 months versus 73 months for received and not received Vitamin. There was no overall survival (OS) difference in luminal A breast cancer that received or did not receive vitamin B12, with median OS 83 months versus 82 months for received and not received Vitamin B12, respectively (SE 2.16-2.73, 95% CI, 0.78 to 0.89; P 0.865), and there was no OS difference in luminal B breast cancer that received or did not receive Vitamin B12, with median OS 81 months versus 80 months for received and not received Vitamin B12, respectively (SE 1.78-2.68, 95% CI, 0.75 to 0.85; P 0.572).

Conclusion: Vitamin B12 had no effect on DFS or OS in luminal A or B early breast cancer patients and can be used safely when indicated.


Sun Y, Lai M-S, Lu C-J. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan. 2005;14(2):48–54.

Beshna E, Amir S, Swead RT, Aldoubali KA, Ashour AM, Benzaed S, et al. Perception, knowledge and attitude of solar radiation diseases and use of sun screen among Al Zawia Medical University Students in Libya. Medical and Pharmaceutical Journal. 2022;1(2):34–44. DOI: 10.55940/medphar202223

Didangelos T, Karlafti E, Kotzakioulafi E, Margariti E, Giannoulaki P, Batanis G, et al. Vitamin B12 supplementation in diabetic neuropathy: A 1-year, randomized, double-blind, placebo-controlled trial. Nutrients [Internet]. 2021;13(2):395. DOI: 10.3390/nu13020395

Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer. 2017;25(1):195–204. DOI: 10.1007/s00520-016-3404-y

Schloss JM, Colosimo M, Vitetta L. Chemotherapy-induced peripheral neuropathy management. Journal of Clinical Oncology. 2016;34(3_suppl):154–154. DOI: 10.1200/jco.2016.34.3

Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer. 2005;13(10):806–11. DOI: 10.1007/s00520-004-0770-7

Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF, et al. The role of dietary supplements during cancer therapy. J Nutr [Internet]. 2003;133(11 Suppl 1):3794S-3799S. DOI: 10.1093/jn/133.11.3794S

Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):243–74. DOI: 10.3322/caac.21142

Diet, nutrition, physical activity and breast cancer [Internet]. [cited 2023 Mar 31]. Available from:

Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J Clin Oncol. 2020;38(8):804–14. DOI: 10.1200/JCO.19.01203

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. DOI: 10.3322/caac.21708

van de Lagemaat EE, de Groot LCPGM, van den Heuvel EGHM. Vitamin B12 in relation to oxidative stress: A systematic review. Nutrients. 2019;11(2):482. DOI: 10.3390/nu11020482

Teven CM, Schmid DB, Sisco M, Ward J, Howard MA. Systemic therapy for early-stage breast cancer: What the plastic surgeon should know. Eplasty. 2017;17:e7.

Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, et al. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2010;28(28):4354–63. DOI: 10.1200/jco.2010.28.0362

Arendt JFH, Farkas DK, Pedersen L, Nexo E, Sørensen HT. Elevated plasma vitamin B12 levels and cancer prognosis: A population-based cohort study. Cancer Epidemiol. 2016;40:158–65. DOI: 10.1016/j.canep.2015.12.007

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23. DOI: 10.1093/annonc/mdt303

 Comparison between patients who received vitamin B12 and those who did not receive  vitamin B12 regarding the overall survival in luminal B




How to Cite

Shaaban, S. M., Gaber, Z., Semary, S., & Dewidar, A. M. (2023). Impact of Vitamin B12 on outcome of Early Stage Luminal A and B Breast Cancer, single center experience. Medical and Pharmaceutical Journal, 2(1), 17–27.